Melanoma is one of the most prevalent malignancies and has a very poor prognosis. Muta‐-
tions in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) occur in approximately …

BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients
with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in …

Introduction: Malignant melanoma (MM) is an aggressive disease with a rapidly rising
incidence due to neoplasm of melanocytes. Molecular targeted therapies have …

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …

Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …

Mitogen-activated protein kinase (MAPK) pathway has an important role in normal cells and
can be activated under physiological conditions. MAPK pathway activation is a fundamental …

Background Several recent randomized clinical trials have preliminarily demonstrated that
initial targeted therapy with combined BRAF and MEK inhibition is more effective in …

Raf-mitogen-activated protein kinase (Raf-MAPK) pathway inhibition with the BRAF
inhibitors vemurafenib and dabrafenib, alone or in combination with a MEK inhibitor, has …

BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive
metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four …

Introduction: BRAF inhibition alone has achieved unprecedented efficacy results in patients
affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that …